Abstract
Breast cancer mortality in women is largely attributed to the metastasis of primary breast tumors. We have analysed the function of EphB6, a kinase-deficient receptor, in the invasive phenotype of breast cancer cell lines. We have demonstrated the loss of EphB6 protein in invasive breast carcinoma cell lines and absence of EphB6 transcript in a metastatic breast tumor specimen. The function of EphB6 in invasiveness was confirmed by the ability of EphB6 protein to decrease the in vitro invasiveness of MDA-MB-231, MDA-MB-435 and BT549 cells transfected with an EphB6 expression construct. In MDA-MB-231 cells, the decreased invasiveness appeared to be mediated by decreased transcript levels of matrix metalloproteinase (MMP)7 and MMP19, and increased transcript levels of tissue inhibitors of metalloproteinase 2. In addition to affecting invasiveness phenotype, EphB6 overexpression was also responsible for altering the growth rate and colony-forming efficiency of MCF-7 and MDA-MB-231 cells in a cell-line-specific manner. We suggest that the significant decrease in the invasiveness of MDA-MB-231 and other cell lines transfected with EphB6 is likely occurring by the ability of EphB6 to transduce signals to the nucleus and altering relevant gene expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams RH . (2002). Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol 13: 55–60.
Ahonen M, Poukkula M, Baker AH, Kashiwagi M, Nagase H, Eriksson JE et al. (2003). Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 22: 2121–2134.
Bashyam MD . (2002). Understanding cancer metastasis: an urgent need for using differential gene expression analysis. Cancer 94: 1821–1829.
Bond M, Murphy G, Bennett MR, Newby AC, Baker AH . (2002). Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 277: 13787–13795.
Bong YS, Lee HS, Carim-Todd L, Mood K, Nishanian TG, Tessarollo L et al. (2007). Ephrin B1 signals from the cell surface to the nucleus by recruitment of STAT3. Proc Natl Acad Sci USA 104: 17305–17310.
Cailleau R, Young R, Olivé M, Reeves Jr WJ . (1974). Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53: 661–674.
Campbell TN, Robbins SM . (2008). The Eph receptor/ephrin system: an emerging player in the invasion game. Curr Issues Mol Biol 10: 61–66.
Chambers AF, Groom AC, MacDonald IC . (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563–572.
Drescher U . (1997). The Eph family in the patterning of neural development. Curr Biol 7: R799–R807.
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE . (2004). Ligation of EphA2 by ephrinA1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 320: 1096–1102.
Elowe S, Holland SJ, Kulkarni S, Pawson T . (2001). Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol 21: 7429–7441.
Fata JE, Leco KJ, Voura EB, Yu HY, Waterhouse P, Murphy G et al. (2001). Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest 108: 831–841.
Fidler IJ . (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3: 453–458.
Fox BP, Kandpal RP . (2004). Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318: 882–892.
Freywald A, Sharfe N, Roifman CM . (2002). The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1. J Biol Chem 277: 3823–3828.
Freywald A, Sharfe N, Rashotte C, Grunberger T, Roifman CM . (2003). The EphB6 receptor inhibits JNK activation in T lymphocytes and modulates T cell receptor-mediated responses. J Biol Chem 278: 10150–10156.
Hafner C, Bataille F, Meyer S, Becker B, Roesch A, Landthaler M et al. (2003). Loss of EphB6 expression in metastatic melanoma. Int J Oncol 23: 1553–1559.
Himanen JP, Nikolov DB . (2003). Molecules in focus. Eph receptors and ephrins. Int J Biochem Cell Biol 35: 130–134.
Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD et al. (2004). Repelling class discrimination: ephrin A5 binds to and activates EphB2 receptor signaling. Nat Neurosci 7: 501–509.
Hojilla CV, Mohammed FF, Khokha R . (2003). Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 89: 1817–1821.
Holmberg J, Clarke DL, Frisén J . (2000). Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 408: 203–206.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71–96.
Kagara N, Tanaka N, Noguchi S, Hirano T . (2007). Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells. Cancer Sci 98: 692–697.
Kullander K, Klein R . (2002). Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol 3: 475–486.
Lai KO, Chen Y, Po HM, Lok KC, Gong K, Ip NY . (2004). Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle: implications in the regulation of acetylcholinesterase expression. J Biol Chem 279: 13383–13392.
Luo H, Wan X, Wu Y, Wu J . (2001). Cross-linking of EphB6 resulting in signal transduction and apoptosis in Jurkat cells. J Immun 167: 1362–1370.
Madsen MW, Briand P . (1990). Relationship between tumorigenicity, in vitro invasiveness, and plasminogen activator production of human breast cell lines. Eur J Cancer 26: 793–797.
Malemud CJ . (2006). Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11: 1696–1701.
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S . (2002). The protein kinase complement of the human genome. Science 298: 1912–1934.
Matsuoka H, Iwata N, Ito M, Shimoyama M, Nagata A, Chihara K et al. (1997). Expression of a kinase-defective Eph-like receptor in the normal human brain. Biochem Biophys Res Commun 235: 487–492.
Matsuoka H, Obama H, Kelly ML, Matsui T, Nakamoto M . (2005). Biphasic function of the kinase-defective EphB6 receptor in cell adhesion and migration. J Biol Chem 280: 29355–29363.
Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR et al. (2001). Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 3: 527–530.
Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, Sanchez OH et al. (2004). Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet 36: 934–935.
Müller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwäble J et al. (2005). Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 65: 1778–1782.
Munthe E, Rian E, Holien T, Rasmussen A, Levy FO, Aasheim H . (2000). Ephrin-B2 is a candidate ligand for the Eph receptor, EphB6. FEBS Lett 466: 169–174.
Nagaraja GM, Kandpal RP . (2004). Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins. Biochem Biophys Res Commun 313: 654–665.
Nagaraja GM, Othman M, Fox BP, Alsabar R, Pellegrino CM, Zeng Y et al. (2006). Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profile by representational difference analysis, microarrays and proteomics. Oncogene 25: 2328–2338.
Nakamoto M . (2000). Molecules in focus. Eph receptors and ephrins. Int J Biochem Cell Biol 32: 7–12.
Noren NK, Foos G, Hauser CA, Pasquale EB . (2006). The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8: 815–825.
Pasquale EB . (2005). Eph receptor signalling casts a wide net on cell behavior. Nat Rev Mol Cell Biol 6: 462–475.
Pratt RL, Kinch MS . (2003). Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. Mol Cancer Res 1: 1070–1076.
Schagdarsurengin U, Pfeifer GP, Dammann R . (2007). Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene 26: 3089–3094.
Soule HD, Vazguez J, Long A, Albert S, Brennan M . (1973). A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409–1416.
Surawska H, Ma PC, Salgia R . (2004). The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15: 419–433.
Tanaka M, Sasaki K, Kamata R, Sakai R . (2007). The C-terminus of ephrin-B1 regulates metalloproteinase secretion and invasion of cancer cells. J Cell Sci 120: 2179–2189.
Tang XX, Zhao H, Robinson ME, Cnaan A, London W, Cohn SL et al. (2000). Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. Med Pediatr Oncol 35: 656–658.
Tang XX, Evans AE, Zhao H, Cnaan A, Brodeur GM, Ikegaki N . (2001). Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. Med Pediatr Oncol 36: 80–82.
Tang XX, Robinson ME, Riceberg JS, Kim DY, Kung B, Titus TB et al. (2004). Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin Cancer Res 10: 5837–5844.
Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R et al. (1992). Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534–544.
Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N et al. (1999). Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Res Treat 56: 91–97.
Xu Q, Wilkinson DG . (1997). Eph-related receptors and their ligands: mediators of contact dependent cell interactions. J Mol Med 75: 576–586.
Yu WH, Yu S, Meng Q, Brew K, Woessner Jr JF . (2000). TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 40: 31226–31232.
Zou JX, Wang B, Kalo MS, Zisch AH, Pasquale EB, Ruoslahti E . (1999). An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci USA 96: 13813–13818.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fox, B., Kandpal, R. EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. Oncogene 28, 1706–1713 (2009). https://doi.org/10.1038/onc.2009.18
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.18
Keywords
This article is cited by
-
EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression
Experimental & Molecular Medicine (2019)
-
Loss of the EPH receptor B6 contributes to colorectal cancer metastasis
Scientific Reports (2017)
-
Continued use of MDA-MB-435, a melanoma cell line, as a model for human breast cancer, even in year, 2014
npj Breast Cancer (2015)
-
Therapeutic targeting of EPH receptors and their ligands
Nature Reviews Drug Discovery (2014)
-
Pregnancy complicated by obesity induces global transcript expression alterations in visceral and subcutaneous fat
Molecular Genetics and Genomics (2014)